ライフサイエンスコーパス: oropharyngeal

1 vulvar, penile, anal, tongue, tonsillar, and oropharyngeal).

2 ), typhoidal (10%), oculoglandular (3%), and oropharyngeal (2%) forms.

3 suited for the somatotopic representation of oropharyngeal and bodily surfaces, arise by radial migra

4 of various cancers including penile, vulva, oropharyngeal and cervical cancers.

5 Oropharyngeal and hypopharyngeal cancer made up the larg

6 serotype M3 group A streptococci (GAS) from oropharyngeal and invasive infections in Ontario recentl

7 ffects on growth, adhesion, and virulence of oropharyngeal and lung isolates of E. coli, suggesting t

8 Joint consideration of results from oropharyngeal and nasal swabs was as effective as consid

9 severe acute respiratory illness (SARI) had oropharyngeal and nasopharyngeal samples collected.

10 We tested oropharyngeal and/or nasopharyngeal swabs for C. pneumon

11 ecretory protein that is expressed in nasal, oropharyngeal, and lung epithelia, and has been implicat

12 compared the performance of nasopharyngeal, oropharyngeal, and nasal swabs for the detection of infl

13 A viruses that are responsible for cervical, oropharyngeal, and various genitourinary cancers.

14 in never smokers and never drinkers, and for oropharyngeal as opposed to oral cavity cancer.

15 sponses in C57BL/6 mice to ENMs delivered by oropharyngeal aspiration (OPA), and three labs evaluated

16 To address this gap, we developed an oropharyngeal aspiration model of lethal and sublethal S

17 Oropharyngeal aspiration of DPPIV inhibits the bleomycin

18 C57Bl/6 mice were examined after oropharyngeal aspiration of recombinant leptin alone or

19 Mouse dams were intermittently exposed via oropharyngeal aspiration to diesel exhaust particles (DE

20 extracted, chemically analyzed, and given by oropharyngeal aspiration to mice or cultured with lung s

21 Tg) for HLA-DP2 to beryllium oxide (BeO) via oropharyngeal aspiration.

22 citrate-coated AgNPs or citrate buffer using oropharyngeal aspiration.

23 xposed to MWCNTs (10 or 40 microg/mouse) via oropharyngeal aspiration.

24 tigens in human papillomavirus (HPV)-related oropharyngeal cancer (HPVOPC) are attractive targets for

25 Human papilloma virus-16 (HPV-16) associated oropharyngeal cancer (HPVOPC) is increasing alarmingly i

26 ents with human papillomavirus (HPV)-related oropharyngeal cancer (OPC) generally present with more a

27 en identified as the cause of the increasing oropharyngeal cancer (OPC) incidence in some countries.

28 iation with or without chemotherapy to treat oropharyngeal cancer (OPC) is supported by evidence from

29 nsible for the rising worldwide incidence of oropharyngeal cancer (OPC).

30 women were over-represented among women with oropharyngeal cancer (OR, 3.2; 95% CI, 1.7 to 6.0).

31 The increased risk of oropharyngeal cancer among HPV16 E6 seropositive partici

32 also related to the increasing incidence of oropharyngeal cancer among young men.

33 iagnostic samples for 34.8% of patients with oropharyngeal cancer and 0.6% of controls (OR, 274; 95%

34 PK pathway was significantly associated with oropharyngeal cancer and cervical cancer, and TGFbetaR1

35 TGFbeta signaling in the development of both oropharyngeal cancer and cervical cancer.

36 s been implicated in the rising incidence of oropharyngeal cancer and has led to variety of studies e

37 human papillomavirus 16 (HPV16) and HPV18 in oropharyngeal cancer and hepatitis B and C viruses in li

38 d genes is associated with susceptibility to oropharyngeal cancer and implicates TGFbetaR1/TGFbeta si

39 genes is a determinant of susceptibility to oropharyngeal cancer and other HPV-associated cancers by

40 Oropharyngeal cancer associations were limited to the hu

41 tier integrative computational analysis with oropharyngeal cancer data from a head and neck cancer ge

42 tivity was present more than 10 years before oropharyngeal cancer diagnosis and was nearly absent in

43 xample, why does the increase in HPV-related oropharyngeal cancer dominate in men?

44 study included patients with non-metastatic oropharyngeal cancer from seven cancer centres located a

45 Many prognostic algorithms for oropharyngeal cancer incorporate HPV status as a stratif

46 Human papillomavirus-related (HPV+) oropharyngeal cancer is a rapidly emerging disease with

47 The biology of HPV-positive oropharyngeal cancer is distinct with P53 degradation, r

48 Our proposed ICON-S staging system for HPV+ oropharyngeal cancer is suitable for the 8th edition of

49 The International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S) aimed

50 d system, the International Collaboration on Oropharyngeal Cancer Network for Staging (ICON-S); and a

51 Risk of oropharyngeal cancer progression and death increases dir

52 survival rates in p16-positive patients with oropharyngeal cancer support the ongoing efforts to expl

53 ampled blood from patients with stage III-IV oropharyngeal cancer undergoing concomitant chemoradioth

54 ll-cause mortality ratio among patients with oropharyngeal cancer was 0.30 (95% CI, 0.13 to 0.67), fo

55 Of 1907 patients with HPV+ oropharyngeal cancer, 661 (35%) were recruited at the tr

56 A total of 84% of the patients had oropharyngeal cancer, and 75% had tumor specimens that s

57 incidence data for cervical adenocarcinoma, oropharyngeal cancer, and anal cancer.

58 can cause cervical and other anogenital and oropharyngeal cancer, and other types of HPV are associa

59 l cancer, and TGFbetaR1 was overexpressed in oropharyngeal cancer, cervical cancer, and HPV(+) head a

60 5% confidence interval (CI), 0.13-0.61] from oropharyngeal cancer, closely followed by high viral loa

61 Human papillomavirus-associated oropharyngeal cancer, in particular, is increasing in in

62 For oropharyngeal cancer, p16-positive patients had better O

63 PV) integration into the host genome in oral/oropharyngeal cancer, reviewed the literature for HPV-in

64 in a five-generation pedigree and comprises oropharyngeal cancer, skin telangiectases, and mild deve

65 ansform cells and contribute to cervical and oropharyngeal cancer, there clearly is much more to lear

66 ical cancer and a major cause of genital and oropharyngeal cancer.

67 , the presumed precursor of HPV16-associated oropharyngeal cancer.

68 s and pathways significantly associated with oropharyngeal cancer.

69 virus (HPV) develop HPV-related cervical and oropharyngeal cancer.

70 ecognized as important causative factors for oropharyngeal cancer.

71 ded (IGRT) radiotherapy for locally advanced oropharyngeal cancer.

72 finger protein genes on chromosome 19q13 in oropharyngeal cancer.

73 stic factor for survival among patients with oropharyngeal cancer.

74 rade 3, and 5.51 (95% CI, 1.22 to 24.84) for oropharyngeal cancer.

75 evelop a TNM classification specific to HPV+ oropharyngeal cancer.

76 derive new staging classifications for HPV+ oropharyngeal cancer.

77 al oncogenic HPV infections and HPV-positive oropharyngeal cancers among men than women arises in par

78 ence of human papilloma virus (HPV)-positive oropharyngeal cancers has risen rapidly in recent decade

79 infection is causing an increasing number of oropharyngeal cancers in the United States and Europe.

80 ecent increases in incidence and survival of oropharyngeal cancers in the United States have been att

81 e population-level incidence and survival of oropharyngeal cancers in the United States since 1984 ar

82 papillomavirus (HPV) causes the majority of oropharyngeal cancers in the United States, yet the risk

83 Population-level incidence of HPV-positive oropharyngeal cancers increased by 225% (95% CI, 208% to

84 continue, the annual number of HPV-positive oropharyngeal cancers is expected to surpass the annual

85 dence of human papillomavirus (HPV)-positive oropharyngeal cancers is higher and increasing more rapi

86 HPV prevalence in oropharyngeal cancers significantly increased over calen

87 ncurrent chemoradiation for locally advanced oropharyngeal cancers was conducted.

88 bserved HPV prevalence was reweighted to all oropharyngeal cancers within the cancer registries to ac

89 an papillomavirus (HPV) cause anogenital and oropharyngeal cancers, whereas cutaneous types (e.g. HPV

90 V-16) and HPV-18 cause a large proportion of oropharyngeal cancers, which are increasing in incidence

91 ausative agents of anogenital tract and some oropharyngeal cancers.

92 ers and a proportion of other anogenital and oropharyngeal cancers.

93 an papillomavirus (HPV)-associated anal than oropharyngeal cancers.

94 s (HPVs) are a major cause of anogenital and oropharyngeal cancers.

95 lomavirus (HPV) infection causes a subset of oropharyngeal cancers.

96 worldwide, notably cervical, anogenital, and oropharyngeal cancers.

97 esent more than 10 years before diagnosis of oropharyngeal cancers.

98 tained current data for HPV-related oral and oropharyngeal cancers.

99 a major cause of noncervical anogenital and oropharyngeal cancers.

100 fection, the principal cause of HPV-positive oropharyngeal cancers.

101 pe associated with cervical, anogenital, and oropharyngeal cancers.

102 ive agents of cervical, anal as well as many oropharyngeal cancers.

103 and reducing the morbidity of treatments for oropharyngeal cancers.

104 Oropharyngeal candidiasis (OPC [thrush]) is an opportuni

105 -17 receptor (IL-17R) is required to prevent oropharyngeal candidiasis (OPC) in mice and humans.

106 Oropharyngeal candidiasis (OPC) is among the most common

107 Oropharyngeal candidiasis (OPC) is an opportunistic fung

108 Isolated oropharyngeal candidiasis (OPC) was the most common pres

109 Oropharyngeal candidiasis (OPC), caused by the commensal

110 ungus Candida albicans is the major cause of oropharyngeal candidiasis (OPC).

111 Oropharyngeal candidiasis (OPC; thrush) is an opportunis

112 ogy of which mimics that of pseudomembranous oropharyngeal candidiasis in humans.

113 Oropharyngeal candidiasis is a frequent cause of morbidi

114 One important line of defense against oropharyngeal candidiasis is the oral microbiota that pr

115 By using a mouse model of oropharyngeal candidiasis we found that IL-17A and IL-17

116 and reduced interleukin-17 signalling during oropharyngeal candidiasis, resulting in more severe dise

117 ard Candida albicans, the causative agent of oropharyngeal candidiasis.

118 Here we describe a simple mouse model of oropharyngeal candidiasis.

119 tion, and fungal burden in a murine model of oropharyngeal candidiasis.

120 Human papillomavirus-related oropharyngeal carcinoma (HPV-OPC) is increasing in incid

121 Patients with p16-positive oropharyngeal carcinoma (OPC), compared with patients wi

122 human papillomavirus is well established in oropharyngeal carcinoma, it has not been proven in the p

123 tolerability for patients with HPV-positive oropharyngeal carcinoma.

124 rticipants were randomly assigned to receive oropharyngeal care with povidone-iodine (n = 91) or plac

125 ncidence as well as significant reduction of oropharyngeal carriage of group A meningococci in vaccin

126 dren aged <5 years annually), as did the Hib oropharyngeal carriage rate (0.9%).

127 ria enriched in lung against a background of oropharyngeal carryover.

128 Stratified analyses on a subgroup of oropharyngeal cases with information available on human

129 ranscription-PCR (RT-PCR) was used to screen oropharyngeal/cloacal swab and brain samples from wild C

130 idin could be of clinical interest to reduce oropharyngeal colonization and prevent lung infection.

131 GAS human epithelial cell adhesion and mouse oropharyngeal colonization but did not affect GAS invasi

132 Concurrent nasal and/or oropharyngeal colonization was also associated with an i

133 of fungal and bacterial taxa, and find that oropharyngeal communities rich in Candida are also rich

134 ity increased significantly over time in the oropharyngeal compartment (P = 0.004).

135 tients with symptoms such as abdominal pain, oropharyngeal complaints, neck lumps, and B-symptoms.

136 These findings suggest that oropharyngeal contamination could limit the accuracy of

137 k factors in women, clinical significance of oropharyngeal CT detection, acceptability and performanc

138 Anterior nares and oropharyngeal cultures were collected.

139 n of the digestive tract (SDD) and selective oropharyngeal decontamination (SOD) are prophylactic ant

140 elective digestive decontamination/selective oropharyngeal decontamination and those receiving standa

141 tive digestive decontamination and selective oropharyngeal decontamination in 16 ICUs in The Netherla

142 ropharyngeal prophylactic methods (selective oropharyngeal decontamination, patient position, sinusit

143 elective digestive decontamination/selective oropharyngeal decontamination.

144 We demonstrate that oropharyngeal delivery of low-dose LPS can immunological

145 Finally, we demonstrated that oropharyngeal delivery of synthetic CpG-oligonucleotides

146 ith significant enhanced overall survival in oropharyngeal disease (HR(DNA) = 0.9, 95% CI = 0.3-2.9;

147 associated with enhanced overall survival in oropharyngeal disease (HR(DNA+/E6/E7+) = 0.1, 95% CI = 0

148 7 seropositivity had favorable survival from oropharyngeal disease (HR(p16+/E6/E7+) = 0.1, 95% CI = 0

149 sociated with enhanced all-cause survival in oropharyngeal disease [HR(E6/E7+) = 0.1, 95% confidence

150 enomic study to determine the composition of oropharyngeal DNA viral communities (both phage and euka

151 stinguishing true oesophageal dysphagia from oropharyngeal dysphagia or other causes.

152 ory tract will contain smaller quantities of oropharyngeal flora and be more likely to have a predomi

153 Using isolation of low quantities of oropharyngeal flora and higher prevalence of potential p

154 rom induced sputum specimens and quantity of oropharyngeal flora were compared for different quantiti

155 g has significant impact on the gingival and oropharyngeal flora.

156 The quantities of viral RNA shed in oropharyngeal fluid during FMDV persistence were similar

157 sarcomas and highest for cervical cancer and oropharyngeal head and neck cancer.

158 Clearance of anogenital and oropharyngeal HPV infections is attributed primarily to

159 Severe oropharyngeal injuries (P = 0.015), increased levels of

160 tered 2 or 4 g/kg of ethanol 30 min prior to oropharyngeal inoculation of 2 x 10(7) CFU of USA300.

161 gher in patients with submucosal (abdominal, oropharyngeal-laryngeal) attacks (3095 [890-10000] mug/l

162 e velum (86%), followed by the tongue (57%), oropharyngeal lateral wall (49%), and epiglottis (26%).

163 h high (>6.9 log10 copies/mL) nasopharyngeal/oropharyngeal load and C-reactive protein >/=40 mg/L (bo

164 activity and follicular immunoreactivity in oropharyngeal lymphoid tissues at 1 and 2 months postexp

165 l phase of prion amplification occurs in the oropharyngeal lymphoid tissues followed by rapid dissemi

166 th initial prion replication in the draining oropharyngeal lymphoid tissues, rapidly followed by diss

167 Although oropharyngeal microbes have been well described, viral c

168 Early identification of deficient oropharyngeal motor skills and vocal cord dysfunction is

169 miR-155 was significantly upregulated in the oropharyngeal mucosa during chronic SIV infection and wa

170 mitted virus, viral transmission through the oropharyngeal mucosal epithelium is not well understood.

171 Here, the authors show that oropharyngeal mucosal infection of macaques with a high

172 Oropharyngeal mucositis was less severe in the Tac/Sir a

173 m outcomes, more rapid engraftment, and less oropharyngeal mucositis, the combination of Tac/Sir is a

174 fastidious, Gram-negative bacterium with an oropharyngeal/nasopharyngeal carriage niche that is asso

175 on by multiplex PCR in IS and nasopharyngeal/oropharyngeal (NP/OP) specimens.

176 a Nairobi slum, we collected nasopharyngeal/oropharyngeal (NP/OP) swab specimens from patients with

177 nostic platforms often use nasopharyngeal or oropharyngeal (NP/OP) swabs for pathogen detection for p

178 Nasopharyngeal/oropharyngeal (NP/OP) swabs from 70 children <5 years wi

179 stigating pathogens in blood, nasopharyngeal/oropharyngeal (NP/OP) swabs, and induced sputum by cultu

180 pneumococcal carriage and nasopharyngeal and oropharyngeal NTHi carriage in 13 541 samples collected

181 VA)-sensitized BALB/cJ mice were exposed via oropharyngeal (OP) aspiration to 20 or 100 mug of each P

182 Aspiration of oropharyngeal or gastric contents into the lower respira

183 Aspiration of oropharyngeal or gastric contents into the respiratory t

184 compared to "RSV pneumonia" (nasopharyngeal/oropharyngeal or induced sputum PCR-positive without con

185 tion of beta1-HPV-5 type was associated with oropharyngeal (OR, 7.42; 95% CI, 0.98-56.82; P = .054),

186 comparable titers in chickens, with superior oropharyngeal over cloacal shedding; both viruses transm

187 Cough (P = .143) and oropharyngeal pain (P = .083) were also reduced in infec

188 The human oropharyngeal pathogen Aggregatibacter actinomycetemcomi

189 ention of gravity-dependent translocation of oropharyngeal pathogens and development of ventilator-as

190 ainage, silver-coated endotracheal tubes) or oropharyngeal prophylactic methods (selective oropharyng

191 as and premalignancies of the anogenital and oropharyngeal region after a CIN3 diagnosis.

192 plays crucial roles in the patterning of the oropharyngeal region and development of muscles derived

193 ional significance of Dlx5 in patterning the oropharyngeal region has remained unknown.

194 o several other tumors of the anogenital and oropharyngeal regions.

195 CV-1 were found in a significant fraction of oropharyngeal samples from a healthy human cohort.

196 It was recently reported that 44% of the oropharyngeal samples from the healthy humans in a study

197 tive PCR with ATCV-1 DNA being documented in oropharyngeal samples obtained from 40 (43.5%) of 92 ind

198 sence of azithromycin-resistant organisms in oropharyngeal samples, along with adverse events, were a

199 We analyzed 25 521 oropharyngeal samples, of which 22 093 were obtained aft

200 genomic analysis of DNA extracted from human oropharyngeal samples.

201 CI, 2.2-22.6), with positive association for oropharyngeal SCC (OR, 22.4; 95% CI, 1.8-276.7), but not

202 r time to survival in patients with oral and oropharyngeal SCC and may provide prognostic information

203 cell carcinoma (SCC), and the prevalence of oropharyngeal SCC is higher among men than women in the

204 patients with histologically proven oral or oropharyngeal SCC underwent PET/CT for initial cancer st

205 therapy in human papilloma virus-associated oropharyngeal SCC, we hypothesized that adding cetuximab

206 t HPV-16 detection precedes the incidence of oropharyngeal SCC.

207 ing sex differences in risk for HPV-positive oropharyngeal SCC.

208 rson to person via fomites contaminated with oropharyngeal secretions containing biofilm streptococci

209 s above horizontal to assess 1 hr leakage of oropharyngeal secretions simulant at cuff internal press

210 roken skin and/or mucosa with saliva, tears, oropharyngeal secretions, cerebrospinal fluid, and neura

211 The quantity of oropharyngeal shedding by contacts was associated with H

212 nce of a sustained cloacal shedding (and not oropharyngeal shedding) was critical for transmission.

213 d progression to cancer at both cervical and oropharyngeal sites as these appear to be distinct.

214 nical data, 1 nasopharyngeal specimen, and 1 oropharyngeal specimen were collected.

215 4025 systematically selected nasopharyngeal-oropharyngeal specimens (24%) were tested for respirator

216 of the 2009 H1N1 virus in nasopharyngeal and oropharyngeal specimens and through information obtained

217 Nasopharyngeal and oropharyngeal specimens from hospitalized patients with

218 Nasopharyngeal and oropharyngeal specimens were collected from April 2007 t

219 Nasopharyngeal and oropharyngeal specimens were collected from patients hos

220 Nasopharyngeal/oropharyngeal specimens were tested for HBoV mRNA and ge

221 se chain reaction analysis of nasopharyngeal/oropharyngeal specimens.

222 riminates poorly when applied to HPV-related oropharyngeal squamous cell cancer (OPSCC), leading to c

223 idence of human papillomavirus (HPV)-related oropharyngeal squamous cell carcinoma (OPSCC) has been r

224 The incidence of HPV-related oropharyngeal squamous cell carcinoma (OPSCC) has increa

225 Human papillomavirus (HPV)-negative oropharyngeal squamous cell carcinoma (OPSCC) has shown

226 A rising incidence of oropharyngeal squamous cell carcinoma (OPSCC) incidence

227 urden of human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma (OPSCC) is disprop

228 Purpose Treatment of oropharyngeal squamous cell carcinoma (OPSCC) is evolvin

229 urpose Human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC) is treatme

230 Human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma (OPSCC) represents

231 les from TCGA and a separate dataset of HPV+ oropharyngeal squamous cell carcinoma (OPSCC) samples to

232 ence-based guideline on radiation therapy in oropharyngeal squamous cell carcinoma (OPSCC) that was d

233 of DNA methylation profiles in fresh-frozen oropharyngeal squamous cell carcinoma (OPSCC) tissues an

234 ion, is recognized as a prognostic marker in oropharyngeal squamous cell carcinoma (OPSCC), its preva

235 (TLG) may serve as a prognostic indicator in oropharyngeal squamous cell carcinoma (OPSCC).

236 virus (HPV) are increasingly associated with oropharyngeal squamous cell carcinoma (OPSCC).

237 sociated head-and-neck cancers, inclusive of oropharyngeal squamous cell carcinoma (OSCC) and oral ca

238 mavirus genotype 16 (HPV16) infection causes oropharyngeal squamous cell carcinoma (SCC), and the pre

239 ospective studies have been able to stratify oropharyngeal squamous cell carcinoma based on HPV statu

240 and outcome in human-papillomavirus-positive oropharyngeal squamous cell carcinoma is particularly ne

241 is the principal cause of a distinct form of oropharyngeal squamous cell carcinoma that is increasing

242 provide important prognostic information in oropharyngeal squamous cell carcinoma treated with chemo

243 Treatment of oropharyngeal squamous cell carcinoma with chemoradiothe

244 therapy in human papilloma virus-associated oropharyngeal squamous cell carcinoma, we hypothesized t

245 ck squamous carcinoma (HNSCC)-in particular, oropharyngeal squamous cell carcinoma.

246 elopments in the diagnosis and management of oropharyngeal squamous cell carcinoma.

247 icrobial signatures unique to human oral and oropharyngeal squamous cell carcinomas (OCSCC/OPSCC).

248 Oropharyngeal squamous cell carcinomas (OPSCC) that are

249 nd neck (HNSCC), the increasing incidence of oropharyngeal squamous cell carcinomas (OPSCCs) is attri

250 causative agent for an increasing subset of oropharyngeal squamous cell carcinomas (OPSCCs), and cur

251 rus (HPV) causes an increasing proportion of oropharyngeal squamous cell carcinomas (OPSCCs), particu

252 rus (HPV) causes an increasing proportion of oropharyngeal squamous cell carcinomas (OPSCCs), particu

253 o clinical staging in patients with oral and oropharyngeal squamous cell carcinomas (SCCs).

254 survival among patients with stage III or IV oropharyngeal squamous-cell carcinoma who were enrolled

255 reased the proportion of macrolide-resistant oropharyngeal streptococci (median change, 27.7% [IQR, 0

256 s included macrolide resistance in commensal oropharyngeal streptococci and lung function.

257 Oropharyngeal swab cultures for meningococcal carriage w

258 e was identified in pooled convenience nasal/oropharyngeal swab samples collected from patients with

259 tudents recommended for vaccination provided oropharyngeal swab specimens and completed questionnaire

260 olymerase chain reaction (PCR), and obtained oropharyngeal swab specimens for multiplex PCR from case

261 A total of 4225 oropharyngeal swab specimens from 3802 unique participan

262 A total of 116 oropharyngeal swab specimens obtained from patients at t

263 Oropharyngeal swab specimens were collected weekly from

264 Nasopharyngeal and oropharyngeal swab specimens were obtained from patients

265 Combined conjunctival and oropharyngeal swab specimens were tested by quantitative

266 Nasopharyngeal and oropharyngeal swab specimens were tested for RSV, using

267 The addition of an oropharyngeal swab, compared with use of a nasal swab al

268 l evaluation and provided nasopharyngeal and oropharyngeal swabs and induced sputum (cases only) for

269 Viral DNA was extracted from 19 pooled oropharyngeal swabs and sequenced.

270 Nasopharyngeal and oropharyngeal swabs and structured questionnaires were c

271 uses) in healthy individuals and to evaluate oropharyngeal swabs as a rapid method for viral detectio

272 Meningococci were isolated from oropharyngeal swabs collected before vaccination and at

273 swabs had equal or greater sensitivity than oropharyngeal swabs for detection of respiratory syncyti

274 cies should preferentially be conducted with oropharyngeal swabs for the best sensitivity.

275 e 9 developing country sites, nasopharyngeal/oropharyngeal swabs from children with and without pneum

276 and middle-income countries, nasopharyngeal/oropharyngeal swabs from children with severe pneumonia

277 Oropharyngeal swabs from pediatric outpatients with ILI

278 irus was detected at much higher titers from oropharyngeal swabs than cloacal swabs.

279 gococci obtained from cerebrospinal fluid or oropharyngeal swabs were characterised by conventional m

280 Nasopharyngeal and oropharyngeal swabs were collected during influenza-like

281 Naso- and oropharyngeal swabs were collected from persons with inf

282 Questionnaires and oropharyngeal swabs were collected from students.

283 ess were interviewed, and nasopharyngeal and oropharyngeal swabs were collected to detect respiratory

284 emiologic information, serum, and buccal and oropharyngeal swabs were collected.

285 the added value of collecting both nasal and oropharyngeal swabs, compared with collection of nasal s

286 polymerase chain reaction performed on nasal/oropharyngeal swabs.

287 om lung explant samples, sputum samples, and oropharyngeal swabs.

288 Local reactions, such as gastrointestinal or oropharyngeal symptoms, are common.

289 We therefore propose that oropharyngeal T cells activated by a variety of stimuli

290 ical carcinoma and a subset of tumors in the oropharyngeal tract.

291 s, including those within the anogenital and oropharyngeal tracts.

292 eterozygosity for the ATR locus was noted in oropharyngeal-tumor tissue.

293 rgery is a new approach for the treatment of oropharyngeal tumors.

294 urred at highest frequency in oral cavity or oropharyngeal tumors.

295 ve the majority of genital cancers, and many oropharyngeal tumors.

296 Oropharyngeal, urogenital, and gastrointestinal tissues

297 lavage (BAL) and upper respiratory tract by oropharyngeal wash (OW).

298 using virus genomes amplified directly from oropharyngeal wash specimens and peripheral blood B cell

299 xtracted from bronchiolar lavage samples and oropharyngeal wash.

300 ers mechanical upper airway obstruction from oropharyngeal weakness contributes equally to an increas